Published on
Monday, March 19, 2012
In the midst of pharma and big biotech's charge into
biosimilars, Pfizer
Inc. has apparently concluded that mAbs are higher-value opportunities
than insulin products. Last week the pharma and Biocon
Ltd. ended a deal for biosimilar insulins because Pfizer's priorities
have changed.
Under the 2010 deal, Pfizer
received rights to market Biocon's portfolio of biosimilar insulin products,
including insulin and insulin glargine. Biocon retained co-exclusive rights to
the products in Germany, India and Malaysia. Pfizer had exclusive rights
elsewhere, except in emerging markets where the pharma shared co-exclusive
rights with Biocon's regional partners (see BioCentury, Nov. 15, 2010).